Skip to main content
padlock icon - secure page this page is secure

Open Access ABCB5‐ZEB1 Axis Promotes Invasion and Metastasis in Breast Cancer Cells

Download Article:
(HTML 43.9 kb)
(PDF 3,304.9 kb)
ABCB5 belongs to the ATP-binding cassette (ABC) superfamily, which is recognized for playing a role in the failure of chemotherapy. ABCB5 has also been found to be overexpressed at the transcriptional level in a number of cancer subtypes, including breast cancer. However, the exact mechanism ABCB5 uses on cancer cell metastasis is still unclear. In the present study, we demonstrate that ABCB5 expression was increased in metastatic tissues when compared with nonmetastatic tissues. ABCB5 can significantly enhance metastasis and epithelial‐mesenchymal transition (EMT), while knockdown of ABCB5 inhibited these processes. Microarray analysis indicated that ZEB1 may function as a downstream factor of ABCB5. Furthermore, the expression of ZEB1 in tissues is positively relevant to ABCB5 in breast cancer. Knocking down ZEB1 inhibits ABCB5 ectopic expression-induced migration and invasion, as well as EMT. Taken together, these results helped to realize the oncogene functions of ABCB5 in breast cancer cells and provided a new direction in treating breast cancer.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ABCB5; Breast cancer; Epithelial‐mesenchymal transition (EMT); ZEB1

Document Type: Research Article

Affiliations: 1: Department of Oncology, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China 2: Department of Thoracic Surgery, The Center Hospital of Xi’an, Shaanxi, P.R. China 3: Department of Oncology, Shaanxi Provincial Tumor Hospital, Xi’an, Shaanxi, P.R. China 4: Department of General Surgery, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, P.R. China

Publication date: March 13, 2017

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more